Compare Ascendis Pharma A/S (ASND) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Johnson Controls International PLC — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Johnson Controls International PLC trades at $143.81 (market cap $87.13B). The key difference: Johnson Controls International PLC is far larger — about 4.9× Ascendis Pharma A/S's market cap, and Johnson Controls International PLC pays a 1.12% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | JCI | |
|---|---|---|
Market Cap | $17.74B | $87.13B |
Sector | Health | Industrials |
52-Week High | $277.18 | $148.21 |
52-Week Low | $163.32 | $103.24 |
Enterprise Value | $18.11B | $95.96B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Johnson Controls International (JCI) trades at $142.81, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a net income margin of 14.45% and a consensus analyst price target of $153.67. Recent news highlights expansion in data center cooling and smart home markets, supported by a dividend of $0.40 per share payable in July 2026.
JCI's outlook is supported by earnings momentum and strategic acquisitions, but risks include high valuation multiples and bearish technical indicators. The stock offers potential upside to analyst targets, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
